{"entity":{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","aka":[],"tldr":"Mogamulizumab is an antibody that clears cancerous T cells from the blood in mycosis fungoides and Sézary syndrome, the leukaemic form of skin lymphoma.","summary":"MAVORIC (2018): PFS 7.7 vs 3.1 months versus vorinostat, with the best responses in blood compartment and Sézary syndrome. Approved in Japan (2012) for ATLL and CCR4+ PTCL/CTCL; US/EU 2018 for MF/SS after one systemic therapy. Rash (mogamulizumab-associated rash) and increased GVHD risk after subsequent allogeneic transplant.","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Mogamulizumab","links":[{"label":"MAVORIC (Lancet Oncol 2018)","url":"https://doi.org/10.1016/S1470-2045(18)30379-6"},{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mogamulizumab"},{"label":"Kim et al., Lancet Oncol 2018: MAVORIC, mogamulizumab against vorinostat in previously treated cutaneous T-cell lymphoma","url":"https://doi.org/10.1016/S1470-2045(18)30379-6"},{"label":"Kataoka et al., Nat Genet 2015: integrated molecular analysis of 426 adult T-cell leukaemia/lymphoma cases","url":"https://doi.org/10.1038/ng.3415"}],"tags":["gap-fill"],"related":[],"cancers":["peripheral-t-cell-lymphoma","cutaneous-t-cell-lymphoma"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["ccr4"],"drugs":[],"companies":["kyowa-kirin"],"institutions":[],"pathways":[],"terms":["adcc","fc-effector"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-mavoric-mogamulizumab-lancet-oncol-2018"],"journals":[],"dependsOn":[],"notes":["Lymphoma biology: CCR4 is on the tumour in more than 80% of mycosis fungoides and Sezary syndrome and about 90% of adult T-cell leukaemia/lymphoma, and it is also on regulatory T cells, so the antibody depletes those too. That explains both the rash and the association between giving it shortly before an allogeneic transplant and severe graft-versus-host disease. MAVORIC randomised 372 previously treated patients to mogamulizumab or vorinostat (Kim 2018). In adult T-cell leukaemia/lymphoma, CCR4 is not only expressed but mutated, with gain-of-function truncations of the cytoplasmic tail in about a quarter of cases (Kataoka 2015)."],"brand":"Poteligeo","modality":"Defucosylated anti-CCR4 monoclonal antibody","mechanism":"Binds CCR4 on malignant T cells (and regulatory T cells) and kills them through enhanced ADCC from the afucosylated Fc.","approvals":[{"region":"JP","year":2012,"indication":"Relapsed CCR4+ adult T-cell leukaemia/lymphoma; later PTCL/CTCL"},{"region":"US","year":2018,"indication":"Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy"},{"region":"EU","year":2018,"indication":"MF/SS after ≥1 systemic therapy"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mogamulizumab/","neighbours":{"cancer":[{"id":"adult-t-cell-leukaemia-lymphoma","kind":"cancer","name":"Adult T-cell leukaemia/lymphoma","route":"/cancers/adult-t-cell-leukaemia-lymphoma/"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"mycosis-fungoides","kind":"cancer","name":"Mycosis fungoides","route":"/cancers/mycosis-fungoides/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"}],"company":[{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","route":"/companies/kyowa-kirin/"}],"term":[{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/"},{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/"},{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/"}],"paper":[{"id":"paper-mavoric-mogamulizumab-lancet-oncol-2018","kind":"paper","name":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","route":"/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/"}],"trial":[{"id":"nct04930653","kind":"trial","name":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","route":"/trials/nct04930653/"},{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/"}]}}